// App-Quantinova.ai

AEP158 : Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: European subanalysis of a global patient survey

Researchers

Presenter

  • Heide Siggelkow

Principal Investigators

  • John Germak

  • Claudio Marelli

  • Kristina Chen

  • Helen Dahl-Hansen

  • Elizabeth Glenister

  • Nawal Bent-Ennakhil

  • Davneet Judge

  • Katie Mycock

  • Bart L Clarke

Medical Centers

  • University of Göttingen, Clinic of Gastroenterology and Endocrinology, Göttingen, Germany

  • Shire Human Genetic Therapies, Inc., a Takeda company, US Medical Affairs, Massachusetts, United States

  • Shire International GmbH, Takeda company, Global Medical Affairs, Glattpark-Opfikon (Zurich), Switzerland

  • Shire Human Genetic Therapies, Inc., a Takeda company, Global Outcomes Research Epidemiology Data Sciences Institute, Research and Development, Massachusetts, United States

  • hypoPARA NORGE, Vettre, Norway

  • Parathyroid UK, Yorkshire, United Kingdom

  • Adelphi Real World, Bollington, United Kingdom

  • Mayo Clinic Rochester, Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Minnesota, United States

Locations

  • Germany

  • United States

  • Switzerland

  • Norway

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Hypoparathyroidism

  • Depression

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved